<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANP</journal-id>
<journal-id journal-id-type="hwp">spanp</journal-id>
<journal-title>Australian &amp; New Zealand Journal of Psychiatry</journal-title>
<issn pub-type="ppub">0004-8674</issn>
<issn pub-type="epub">1440-1614</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0004867412464717</article-id>
<article-id pub-id-type="publisher-id">10.1177_0004867412464717</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The nocebo effect: A clinicians guide</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Data-Franco</surname><given-names>João</given-names></name>
<xref ref-type="aff" rid="aff1-0004867412464717">1</xref>
<xref ref-type="aff" rid="aff2-0004867412464717">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Berk</surname><given-names>Michael</given-names></name>
<xref ref-type="aff" rid="aff2-0004867412464717">2</xref>
<xref ref-type="aff" rid="aff3-0004867412464717">3</xref>
<xref ref-type="aff" rid="aff4-0004867412464717">4</xref>
<xref ref-type="aff" rid="aff5-0004867412464717">5</xref>
</contrib>
</contrib-group>
<aff id="aff1-0004867412464717"><label>1</label>Psychiatric Department, Hospital Santa Maria, Lisbon, Portugal</aff>
<aff id="aff2-0004867412464717"><label>2</label>School of Medicine and Barwon Health, Deakin University, Geelong, Australia</aff>
<aff id="aff3-0004867412464717"><label>3</label>Florey Institute for Neuroscience and Mental Health, Parkville, Australia</aff>
<aff id="aff4-0004867412464717"><label>4</label>Department of Psychiatry, University of Melbourne, Parkville, Australia</aff>
<aff id="aff5-0004867412464717"><label>5</label>Orygen Youth Health Research Centre, Parkville, Australia</aff>
<author-notes>
<corresp id="corresp1-0004867412464717">Joao Data-Franco, Psychiatric Department, 4th Floor, Hospital Santa Maria, Avenida Professor Egas Moniz, 1649-035 Lisboa, Portugal. Email: <email>joaodatafranco@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2013</year>
</pub-date>
<volume>47</volume>
<issue>7</issue>
<fpage>617</fpage>
<lpage>623</lpage>
<permissions>
<copyright-statement>© The Royal Australian and New Zealand College of Psychiatrists 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The Royal Australian and New Zealand College of Psychiatrists</copyright-holder>
</permissions>
<abstract>
<sec id="section1-0004867412464717">
<title>Objective:</title>
<p>This paper aims to provide an overview on the nocebo effect, focusing on recognition — its phenomenology, at-risk demographic profiles, clinical situations and personality factors, as well as discriminating somatic symptoms in the general population from treatment-related adverse effects. Lastly, the paper addresses available evidence-based strategies for management and minimisation of the nocebo effect.</p>
</sec>
<sec id="section2-0004867412464717">
<title>Method:</title>
<p>Data for this paper were identified by searching PubMed using the search terms "nocebo" and “nocebo effect”, augmented by a manual search of the references of the key papers and the related literature.</p>
</sec>
<sec id="section3-0004867412464717">
<title>Results:</title>
<p>The nocebo effect refers to non-pharmacodynamic, harmful or undesirable effects occurring after inactive treatment, a phenomenon that also occurs in the context of active therapy. Known drivers include classical conditioning and negative expectations concerning treatment. Recent meta-analyses have reported a considerable prevalence, ranging from 18% in the symptomatic treatment of migraine, to more than 74% in multiple sclerosis. Recognition of the nocebo-driven adverse effects presents a challenge, especially because of its non-specific nature and the similarity to the active medication’s expected profile. Traits such as neuroticism, pessimism and type A personalities may predispose individuals to this phenomenon. Clinical management of the nocebo effect includes awareness and recognition, changing the manner of disclosure of potential drug-related adverse effects, shaping patients’ expectations and enhancing the treatment alliance.</p>
</sec>
<sec id="section4-0004867412464717">
<title>Conclusion:</title>
<p>The nocebo effect is a common, clinically significant, yet covert driver of clinical outcomes. Increased awareness of its features, as well as knowledge of strategies on how to manage it, are fundamental so that clinicians can mitigate its impact on clinical practice.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Nocebo</kwd>
<kwd>placebo</kwd>
<kwd>adverse effects</kwd>
<kwd>treatment outcomes</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section5-0004867412464717" sec-type="intro">
<title>Introduction</title>
<p>The placebo effect (from Latin “I will please”) has attracted much attention, and many studies have been conducted to elicit its prevalence, physiology, impact and management. There is, however, scant data and awareness of its “dark side” — the nocebo effect (from Latin “I will harm”), despite the fact that it may be a significant driver of clinical outcomes. The first description of the nocebo effect was by Kennedy in <xref ref-type="bibr" rid="bibr28-0004867412464717">1961</xref>, after noticing non-specific adverse reactions to drugs, which he hypothesised to have parallels to the placebo effect (<xref ref-type="bibr" rid="bibr28-0004867412464717">Kennedy, 1961</xref>). A classic example of the nocebo phenomenon is illustrated by the experiment of <xref ref-type="bibr" rid="bibr50-0004867412464717">Schweiger and Parducci (1981)</xref>. They recruited a group of students and informed them that they would be subjected to a procedure — administration of electric current to their heads — that could induce headaches. Even though no electricity was administered, the majority of participants reported headache.</p>
<p>The nocebo effect refers to non-pharmacodynamic, harmful, unpleasant, or undesirable effects a person experiences after receiving an inactive treatment. Like the placebo effect, this additionally has the potential to impact on active therapy. <xref ref-type="bibr" rid="bibr25-0004867412464717">Hahn (1997)</xref> expanded this concept, noting that the generation of negative symptoms follows their expectation and associated emotions, and may lead to undesirable effects. Expectation may in some situations be a more potent mediator of clinical response than the treatment itself (<xref ref-type="bibr" rid="bibr11-0004867412464717">Chen et al., 2011</xref>). The nocebo effect may be a cause of adverse reactions and treatment discontinuation. For example, the nocebo effect has been linked to non-adherence to oral contraception. It is not always clear if non-specific side effects of many drugs are more common than with placebo, and such reactions are considered to be one of the main causes of treatment discontinuation (<xref ref-type="bibr" rid="bibr24-0004867412464717">Grimes and Schulz, 2011</xref>). The aim of this paper is to synthesise the latest data on the nocebo effect, focusing on its prevalence and biological and psychological explanations, and to provide information that will help clinicians to recognise and manage this covert mediator of clinical outcomes.</p>
</sec>
<sec id="section6-0004867412464717" sec-type="materials|methods">
<title>Material and methods</title>
<p>Data for this paper were identified by searching PubMed using the search terms “nocebo” and “nocebo effect”, augmented by a manual search of the references of the key papers and the related literature.</p>
</sec>
<sec id="section7-0004867412464717" sec-type="results">
<title>Results</title>
<sec id="section8-0004867412464717">
<title>Prevalence</title>
<p>Data on the prevalence of the nocebo side effects are largely derived from the adverse reactions in the placebo arm of clinical trials. This provides only an estimate, since natural history comparison is not available. In phase one studies of healthy volunteers, the rate of adverse reactions on placebo was 7.9% (<xref ref-type="bibr" rid="bibr52-0004867412464717">Sibille et al., 1998</xref>). A review of 109 double-blind, placebo-controlled studies indicated that around 19% of 1228 healthy participants reported adverse reactions to an inert substance (<xref ref-type="bibr" rid="bibr49-0004867412464717">Rosenzweig et al., 1993</xref>). The clinical population and background symptomatology have a major influence on prevalence; in the placebo arms of two trials of methylphenidate and donepezil for cancer-related fatigue, 71% of the patients reported more than two side effects (<xref ref-type="bibr" rid="bibr17-0004867412464717">De la Cruz et al., 2010</xref>). Recently, a series of meta-analysis has been conducted to estimate the frequency of nocebo effects in several disorders, using adverse effects and drop-out rate in the placebo arm of drug trials (<xref ref-type="table" rid="table1-0004867412464717">Table 1</xref>). Nocebo responses ranged from 18% in the symptomatic treatment of migraine to more than 74% in multiple sclerosis. Treatment discontinuation due to side effects was up to 9.5% in fibromyalgia.</p>
<table-wrap id="table1-0004867412464717" position="float">
<label>Table 1.</label>
<caption>
<p>Meta-analyses of nocebo effects in the placebo arms of clinical trials.</p>
</caption>
<graphic alternate-form-of="table1-0004867412464717" xlink:href="10.1177_0004867412464717-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="left">Disorder</th>
<th align="left">Nocebo rate<sup><xref ref-type="table-fn" rid="table-fn1-0004867412464717">a</xref></sup> (%)</th>
<th align="left">Drop-out rate<sup><xref ref-type="table-fn" rid="table-fn2-0004867412464717">b</xref></sup> (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><xref ref-type="bibr" rid="bibr42-0004867412464717">Papadopoulos and Mitsikostas, 2012</xref></td>
<td>Neuropathic pain</td>
<td>52</td>
<td>6</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr43-0004867412464717">Papadopoulos and Mitsikostas, 2011</xref></td>
<td>Multiple sclerosis</td>
<td>74.42 (DMT)<break/>25.3 (ST)</td>
<td>2.1 (DMT)<break/>2.34 (ST)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr38-0004867412464717">Mitsikostas et al., 2011</xref></td>
<td>Migraine</td>
<td>18.45 (ST)<break/>42.78 (PT)</td>
<td>0.33 (ST)<break/>4.75 (PT)</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr37-0004867412464717">Mitsikostas et al., 2012</xref></td>
<td>Fibromyalgia</td>
<td>67.2</td>
<td>9.5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0004867412464717">
<label>a</label>
<p>Percentage of patients experiencing side effects when taking placebo.</p></fn>
<fn id="table-fn2-0004867412464717">
<label>b</label>
<p>As a result of adverse effects of treatment.</p></fn>
<fn id="table-fn3-0004867412464717">
<p>DMT: disease-modifying treatments; ST: symptomatic treatment; PT: preventive treatment.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>A study of 600 patients with a history of adverse effects to different medications was conducted (<xref ref-type="bibr" rid="bibr32-0004867412464717">Liccardi et al., 2004</xref>). Patients were first challenged with an inert substance, and then with two different concentrations of an active substance that was different from the drug that allegedly induced side effects. The induction of symptoms by the inert agent ranged between 24 and 30% of patients. Male subjects reported fewer side effects (19%) than females (30%). However, a more recent study, using a similar method, reported only a 3% nocebo rate (<xref ref-type="bibr" rid="bibr34-0004867412464717">Lombardi et al., 2008</xref>). The pattern of gender effects has been replicated, with females suffering from panic disorder being more likely than males to develop increased anxiety following administration of an inert substance, a finding also seen in depression (<xref ref-type="bibr" rid="bibr10-0004867412464717">Casper et al., 2001</xref>; <xref ref-type="bibr" rid="bibr54-0004867412464717">Strohle, 2000</xref>). Similarly, medication side effects may be more frequent amongst females (<xref ref-type="bibr" rid="bibr60-0004867412464717">Zopf et al., 2008</xref>).</p>
</sec>
<sec id="section9-0004867412464717">
<title>Aetiology</title>
<p>In part because of a lack of awareness of the nocebo effect, its covert nature, as well as ethical issues in studying unnecessary worsening of symptoms, there is less knowledge about the mechanisms of the nocebo response compared to the placebo effect. Most studies have been carried out in the field of pain. Two dominant psychological mechanisms are thought to be involved in the nocebo response — expectation and classical conditioning (<xref ref-type="bibr" rid="bibr6-0004867412464717">Benedetti et al., 2003</xref>).</p>
</sec>
<sec id="section10-0004867412464717">
<title>Expectation</title>
<p>A paradigmatic example of how expectations are involved in a nocebo effect is the experiment of sham current causing headaches conducted by <xref ref-type="bibr" rid="bibr50-0004867412464717">Schweiger and Parducci (1981)</xref> mentioned above. In another informative study, participants were told that they would receive either an inert or herbal substance, even though all participants ingested an inactive compound. Fully 89% reported it induced at least one symptom; 11% reported only nocebo symptoms, while 28% reported both placebo and nocebo effects (<xref ref-type="bibr" rid="bibr33-0004867412464717">Link et al., 2006</xref>).</p>
<p>In a study using the tourniquet technique to induce ischaemic pain, providing suggestions that the pain would increase led to diminished pain tolerance. Similarly, expectation of nausea in cancer patients undergoing chemotherapy treatment predicted its development (<xref ref-type="bibr" rid="bibr12-0004867412464717">Colagiuri and Zachariae, 2010</xref>). In a study examining the impact of verbal suggestions on the induction of pruritus and pain, both were promoted by the person’s expectation (<xref ref-type="bibr" rid="bibr57-0004867412464717">Van Laarhoven et al., 2011</xref>).</p>
<p>Treatment outcomes are influenced by whether a therapy is overt or hidden. Among people treated with morphine to reduce pain after surgery, delayed rises in pain intensity were reported if they were unaware that the treatment had been stopped, while unconcealed treatment suspension triggered symptom recurrence. Similarly, with diazepam treatment for anxiety, open interruption of diazepam resulted in worsening of anxiety, while concealed suspension did not (<xref ref-type="bibr" rid="bibr13-0004867412464717">Colloca et al., 2004</xref>). In aggregate, these studies support expectancy as a key operative pathway of the nocebo effect.</p>
</sec>
<sec id="section11-0004867412464717">
<title>Classical conditioning</title>
<p>Classical conditioning is another pathway to the nocebo effect. For example, patients who received a lemon-lime beverage (conditioned stimulus) concurrent with administration of chemotherapy reported significantly more nausea than control subjects when the conditioned stimulus was presented again without the chemotherapy agents (<xref ref-type="bibr" rid="bibr9-0004867412464717">Bovbjerg et al., 1992</xref>). The finding that both expectations and prior conditioning are relevant in the development of nocebo-induced hyperalgaesia has been replicated, and it appears that the duration of the conditioning positively influences the perpetuation of the nocebo effect (<xref ref-type="bibr" rid="bibr15-0004867412464717">Colloca et al., 2008</xref>; <xref ref-type="bibr" rid="bibr14-0004867412464717">Colloca et al., 2010</xref>). Clinically, awareness of past adverse experiences should warn the clinician of the probability of nocebo effects intruding into treatment. The genders may differ in terms of the relative role of expectation and conditioning. In men, the nocebo response may be driven more by expectations, while conditioning appears more salient in women (<xref ref-type="bibr" rid="bibr29-0004867412464717">Klosterhalfen et al., 2009</xref>).</p>
</sec>
<sec id="section12-0004867412464717">
<title>Neurobiology of the nocebo phenomenon</title>
<p>Changes in the hypothalamic-pituitary-adrenal axis, including rises in adrenocorticotrophic hormone and cortisol, have been linked to pain perception and expectation (<xref ref-type="bibr" rid="bibr5-0004867412464717">Benedetti et al., 2006</xref>; <xref ref-type="bibr" rid="bibr27-0004867412464717">Johansen et al., 2003</xref>). Cholecystokinin pathways may additionally mediate the link between anxiety and pain in nocebo-induced hyperalgaesia (<xref ref-type="bibr" rid="bibr4-0004867412464717">Benedetti et al., 1997</xref>; <xref ref-type="bibr" rid="bibr5-0004867412464717">Benedetti et al., 2006</xref>). Neuroimaging studies have examined this phenomenon. A positron emission tomography study reported changes in μ-opioid and dopamine D2/D3 neurotransmission with the nocebo effect, and functional magnetic resonance imaging studies have suggested the involvement of specific brain structures, such as anterior cingulate, insula and the prefrontal cortex (<xref ref-type="bibr" rid="bibr30-0004867412464717">Kong et al., 2008</xref>; <xref ref-type="bibr" rid="bibr31-0004867412464717">Koyama et al., 2005</xref>; <xref ref-type="bibr" rid="bibr51-0004867412464717">Scott et al., 2008</xref>).</p>
</sec>
<sec id="section13-0004867412464717">
<title>Recognition</title>
<p>Before management can commence, recognition of the at-risk profile is necessary. Individuals who have high levels of anxiety, somatisation or hypochondriasis, histories of adverse events, trauma or abuse or unsatisfactory experiences with medical care, signs of personality disorder and conflictual relationships with authority figures or systems of care need to be identified. These profiles will be examined in this section.</p>
<sec id="section14-0004867412464717">
<title>Recognising the nocebo response</title>
<p>Characteristically, nocebo-driven adverse events are non-specific (i.e. not necessarily directly linked to the drugs’ pharmacological profile, although knowledge of the potential side effects may drive expectation-driven events), with drowsiness, asthenia, dizziness, nausea and vomiting being the most frequent (<xref ref-type="bibr" rid="bibr49-0004867412464717">Rosenzweig et al., 1993</xref>). One consequence of expectation is that nocebo-driven side effects tend to resemble the ones known to be part of a medication’s profile or the expected symptoms of the disorder, adding opacity to interpretation (<xref ref-type="bibr" rid="bibr37-0004867412464717">Mitsikostas et al., 2012</xref>; <xref ref-type="bibr" rid="bibr47-0004867412464717">Rief et al., 2009</xref>; <xref ref-type="bibr" rid="bibr1-0004867412464717">Amanzio et al., 2009</xref>).</p>
</sec>
<sec id="section15-0004867412464717">
<title>Somatic symptoms</title>
<p>In order to contextualise adverse events, it needs to be noted that physical symptoms not attributable to any disease (somatisation) are frequent in the general population, with prevalence rates of up to 81.6%. The most frequent symptoms are headache, back and joint pain, intolerance to food, and sexual dysfunction. Female gender, old age, lower levels of education and socio-economic status, as well as living in rural regions, are all linked to such symptoms (<xref ref-type="bibr" rid="bibr26-0004867412464717">Hiller et al., 2006</xref>; <xref ref-type="bibr" rid="bibr46-0004867412464717">Rief et al., 2001</xref>). Some adverse effects like headache, fatigue or back pain may even be more frequent in the general population than in trial reports (<xref ref-type="bibr" rid="bibr45-0004867412464717">Rief et al., 2006</xref>). Moreover, subjects may mislabel their symptoms according to prior experiences and expectations, environmental influences, knowledge about the bodily sensations, and different emotional states (<xref ref-type="bibr" rid="bibr35-0004867412464717">Mechanic, 1972</xref>). The proneness to interpret sensations as more distressing, known as “amplification”, is associated with anxiety, depressive and dysphoric mood (<xref ref-type="bibr" rid="bibr2-0004867412464717">Barsky et al., 1988</xref>; <xref ref-type="bibr" rid="bibr56-0004867412464717">Uhlenhuth et al., 1998</xref>). However, not all studies have found a clear link between the nocebo effects and anxiety (<xref ref-type="bibr" rid="bibr33-0004867412464717">Link et al., 2006</xref>). It is plausible that the nocebo effect with an active treatment might overlap with unexpected and unusually prominent side effects reported by patients with a genuine sensitivity to a particular drug, for example, those with significant genetically determined slow metabolism.</p>
</sec>
<sec id="section16-0004867412464717">
<title>Personality</title>
<p>Some studies have addressed the role of personality as a mediator of the nocebo response and adverse event reporting. Traits such as neuroticism, pessimism and type A personalities may increase the risks for such phenomena (<xref ref-type="table" rid="table2-0004867412464717">Table 2</xref>). Linked to personality, one’s prior experiences profoundly mould expectation and outcomes. People who have had prior adverse events or dissatisfaction with medical services are more likely to be guarded, distrustful and expectant of pattern repetition. More broadly, those people who have had adverse early life experiences or trauma histories tend to be more vulnerable to distrust in general and to experience feelings of rejection or abandonment of care. When placed in a situation of need, they may manifest a hostile-dependent pattern of interaction with caregivers, asking for care, but at some level expecting a repeat of prior patterns of interaction. As an exemplar, haemodialysis patients who manifested conflictual relationships with care had developmental histories in which there were major issues with dependency/independency conflicts and more adverse current life circumstances (<xref ref-type="bibr" rid="bibr44-0004867412464717">Procci, 1981</xref>).</p>
<table-wrap id="table2-0004867412464717" position="float">
<label>Table 2.</label>
<caption>
<p>The role of personality in the nocebo effect.</p>
</caption>
<graphic alternate-form-of="table2-0004867412464717" xlink:href="10.1177_0004867412464717-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Study</th>
<th align="left">Objective</th>
<th align="left">Personality measure</th>
<th align="left">Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td><xref ref-type="bibr" rid="bibr22-0004867412464717">Geers, Helfer, et al., 2005</xref></td>
<td>Link between dispositional optimism and nocebo/placebo effects</td>
<td>LOT-R</td>
<td>Pessimists were more prone to the nocebo effect.</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr23-0004867412464717">Geers, Kosbab, et al., 2007</xref></td>
<td>Link between dispositional optimism and nocebo/placebo effects</td>
<td>LOT-R</td>
<td>Pessimists were less likely to demonstrate a placebo effect.</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr19-0004867412464717">Drici, Raybaud, et al., 1995</xref></td>
<td>Influence of personality in reporting of adverse effects</td>
<td>BRS</td>
<td>Individuals with type A personalities reported adverse symptoms after administration of the inert substance more often than type B individuals.</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr16-0004867412464717">Davis, Ralevski, et al., 1995</xref></td>
<td>Influence of personality in reporting of symptoms</td>
<td>EPQ-R</td>
<td>Increased neuroticism was additionally related to increased adverse effect self-reporting during this double-blind, placebo control trial of a reversible inhibitor of monoamine oxidase inhibitor.</td>
</tr>
<tr>
<td><xref ref-type="bibr" rid="bibr21-0004867412464717">Feldman, Cohen, et al., 1999</xref></td>
<td>Influence of personality in reporting of symptoms</td>
<td>Goldberg’s adjective scales (modified version)</td>
<td>Subjects were inoculated with a common cold virus; the intensity and amount of symptoms were increased in those who scored higher on neuroticism both before and after exposure to the virus. People who did not develop the infection but still reported its symptoms had elevated scores on the conscientiousness trait.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0004867412464717">
<p>LOT-R: Revised Life Orientation Test; BRS: Bortner Rating Scale; EPQ-R: Eysenck Personality Questionnaire-Revised.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Involuntary treatment and perceived coercive treatment settings are linked to a lower probability of placebo effects and an increased likelihood of nocebo effects, resulting in a decreased effectiveness of treatment (<xref ref-type="bibr" rid="bibr36-0004867412464717">Meynen and Swaab, 2011</xref>).</p>
</sec></sec>
<sec id="section17-0004867412464717">
<title>Clinical management</title>
<sec id="section18-0004867412464717">
<title>Informed consent</title>
<p>A major factor in the development of the nocebo effect is the manner of disclosure of potential medication adverse effects. In a study on the sexual adverse reactions of finasteride — a drug used to treat benign prostate hyperplasia and androgenetic alopecia — 44% of people who were briefed on the potential occurrence of sexual adverse effects reported them, compared to only 15% of the subjects who were not told (<xref ref-type="bibr" rid="bibr39-0004867412464717">Mondaini et al., 2007</xref>). Similar results using different drugs for different disorders are reported (<xref ref-type="bibr" rid="bibr40-0004867412464717">Myers et al., 1987</xref>; <xref ref-type="bibr" rid="bibr53-0004867412464717">Silvestri et al., 2003</xref>). Thus, the clinician needs to consider how to present information to the patient and that this information can shape the person’s expectations. In a litigious environment, doctors may over-emphasise the risks of treatment for pre-emptive medicolegal reasons, which can increase the risk of inadvertently driving the nocebo effect. In clinical care, this can compromise therapy, and in the context of informed consent for clinical trials, can drive the rate of adverse event reporting.</p>
</sec>
<sec id="section19-0004867412464717">
<title>Presenting information to patients</title>
<p>Physicians as well as patients undertake risk-benefit assessments in decision making. How clinicians present information about risks and benefits of therapies therefore markedly affects the perceptions of the patient, and thereby adherence, engagement and treatment choices. Physicians can transmit their messages to patients in different ways. While not refraining from delivering the necessary information, it may be preferable to bring attention to benefits rather than losses (<xref ref-type="bibr" rid="bibr55-0004867412464717">Thaler and Sunstein, 2008</xref>). This method is called “framing” and it has been suggested to guide patient’s approach and choices regarding treatment and prevention of disease (for a review on ‘framing’, see <xref ref-type="bibr" rid="bibr20-0004867412464717">Edwards et al., 2001</xref>). When discussing side effects, there is some evidence that if doctors make explicit the difference between the probabilities of patients feeling adverse symptoms and their actual prevalence in a general population, they may become less worried about their occurrence (<xref ref-type="bibr" rid="bibr59-0004867412464717">Zikmund-Fisher et al., 2008</xref>). One study of influenza vaccination reported lower absentee rates and adverse effects if the clinical explanation focused on the advantages (i.e. framed as the percentage of people who will remain well and have no side effects) instead of the disadvantages (i.e. patients who will get influenza and develop side effects) (<xref ref-type="bibr" rid="bibr41-0004867412464717">O’Connor et al., 1996</xref>).</p>
</sec>
<sec id="section20-0004867412464717">
<title>Shaping expectations</title>
<p>As an exemplar, it is common for physicians to warn patients of the painful nature of an impending procedure, such as the administration of a local anaesthesia. However, this may have counterproductive effects, as one study reported lower scores for pain if the message was focused on the injection’s beneficial effects, rather than it being painful (<xref ref-type="bibr" rid="bibr58-0004867412464717">Varelmann et al., 2010</xref>).</p>
<p>The treatment alliance and way the medication is prescribed are also factors that may assist the clinician to reduce the likelihood of the nocebo effect. Engaging in a collaborative model of shared decision making is helpful, so that the person has a sense of a degree of both control and ownership and of the decision-making process and the therapeutic decisions. This enhancement of autonomy increases perceived ownership of the conjoint plan, enhances the therapeutic alliance and makes adherence and engagement with treatment more likely (<xref ref-type="bibr" rid="bibr8-0004867412464717">Berk et al., 2004</xref>; <xref ref-type="bibr" rid="bibr7-0004867412464717">Berk et al., 2010</xref>).</p>
</sec>
<sec id="section21-0004867412464717">
<title>Attitude</title>
<p>Di Blasi conducted a systematic review on the effects of context in the effectiveness of treatment. Doctors who were more encouraging, kind and affectionate and provided a clear diagnosis seemed to be more effective in, for instance, reducing perceived pain levels and time to improvement than physicians who adopted a more rigid attitude and did not offer any consolation (<xref ref-type="bibr" rid="bibr18-0004867412464717">Di Blasi et al., 2001</xref>).</p>
</sec>
<sec id="section22-0004867412464717">
<title>Mitigating reaction to side effects</title>
<p>A “two-step strategy” has been proposed to minimise the nocebo phenomenon. Especially in situations where long-term medication is envisaged, the person has a clinical profile that puts him or her at risk for the nocebo effect, where there are few alternatives to the chosen therapy, and where time pressure is not acute (e.g. lithium for maintenance of bipolar disorder), the person should first be started on a dosage of medication that is overtly under what is considered to be therapeutic. The use of a pill cutter to shave chips off a tablet may be a more explicit demonstration of safety than use of a lower dose formulation. Following this, small increases should follow until the desirable dose is achieved. If nonspecific adverse effects do occur, they should be thoroughly discussed with the patient, and the attending physician should take time to explain the benign or time-limited nature of such reactions (<xref ref-type="bibr" rid="bibr3-0004867412464717">Barsky, 2002</xref>; <xref ref-type="bibr" rid="bibr48-0004867412464717">Rogers, 2003</xref>). However, in some cases, the development of adverse reactions will end up being inevitable. When it happens, it may be more helpful and pragmatic to assist patients to cope, rather than attempting to suppress them. A discussion of acceptance of adverse events as a price of health can enhance a sense of acceptance of the treatment choice. Rogers also suggested that telling patients these reactions are benign and mean that the medicine is “in their system” may be helpful (<xref ref-type="bibr" rid="bibr48-0004867412464717">Rogers, 2003</xref>).</p>
</sec></sec>
</sec>
<sec id="section23-0004867412464717" sec-type="conclusions">
<title>Conclusions</title>
<p>The nocebo effect is a significant driver of clinical outcomes. Clinicians need to be aware of its presence and influence, and be able to recognise the phenomenon. There are strategies on how to manage and minimise the nocebo effect, including how to optimally present information to patients, shape their expectations and manage emergent side effects. Only by being aware of potholes can one steer around them.</p>
</sec>
</body>
<back>
<ack><p>All the participating authors have been listed and both authors contributed equally to this review.</p></ack>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.</p></fn>
<fn fn-type="conflict">
<label>Declaration of interest</label>
<p>MB has received grant/research support from the National Institutes of Health (NIH), Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, MBF, National Health and Medical Research Council (NHMRC), Beyond Blue, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Organon, Novartis, Mayne Pharma and Servier, has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth, and served as a consultant to Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck and Servier. JDF has no potential conflicts of interest.</p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Amanzio</surname><given-names>M</given-names></name>
<name><surname>Corazzini</surname><given-names>LL</given-names></name>
<name><surname>Vase</surname><given-names>L</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>A systematic review of adverse events in placebo groups of anti-migraine clinical trials</article-title>. <source>Pain</source> <volume>146</volume>: <fpage>261</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr2-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barsky</surname><given-names>AJ</given-names></name>
<name><surname>Goodson</surname><given-names>JD</given-names></name>
<name><surname>Lane</surname><given-names>RS</given-names></name>
<etal/></person-group>. (<year>1988</year>) <article-title>The amplification of somatic symptoms</article-title>. <source>Psychosomatic Medicine</source> <volume>50</volume>: <fpage>510</fpage>–<lpage>519</lpage>.</citation>
</ref>
<ref id="bibr3-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barsky</surname><given-names>AJ</given-names></name>
<name><surname>Saintfort</surname><given-names>R</given-names></name>
<name><surname>Rogers</surname><given-names>MP</given-names></name>
<etal/></person-group>. (<year>2002</year>) <article-title>Nonspecific medication side effects and the nocebo phenomenon</article-title>. <source>JAMA</source> <volume>287</volume>: <fpage>622</fpage>–<lpage>627</lpage>.</citation>
</ref>
<ref id="bibr4-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benedetti</surname><given-names>F</given-names></name>
<name><surname>Amanzio</surname><given-names>M</given-names></name>
<name><surname>Casadio</surname><given-names>C</given-names></name>
<etal/></person-group>. (<year>1997</year>) <article-title>Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide</article-title>. <source>Pain</source> <volume>71</volume>: <fpage>135</fpage>–<lpage>140</lpage>.</citation>
</ref>
<ref id="bibr5-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benedetti</surname><given-names>F</given-names></name>
<name><surname>Amanzio</surname><given-names>M</given-names></name>
<name><surname>Vighetti</surname><given-names>S</given-names></name>
<etal/></person-group>. (<year>2006</year>) <article-title>The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect</article-title>. <source>Journal of Neuroscience</source> <volume>26</volume>: <fpage>12014</fpage>–<lpage>12022</lpage>.</citation>
</ref>
<ref id="bibr6-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benedetti</surname><given-names>F</given-names></name>
<name><surname>Pollo</surname><given-names>A</given-names></name>
<name><surname>Lopiano</surname><given-names>L</given-names></name>
<etal/></person-group>. (<year>2003</year>) <article-title>Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses</article-title>. <source>Journal of Neuroscience</source> <volume>23</volume>: <fpage>4315</fpage>–<lpage>4323</lpage>.</citation>
</ref>
<ref id="bibr7-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berk</surname><given-names>L</given-names></name>
<name><surname>Hallam</surname><given-names>KT</given-names></name>
<name><surname>Colom</surname><given-names>F</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Enhancing medication adherence in patients with bipolar disorder</article-title>. <source>Human Psychopharmacology</source> <volume>25</volume>: <fpage>1</fpage>–<lpage>16</lpage>.</citation>
</ref>
<ref id="bibr8-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berk</surname><given-names>M</given-names></name>
<name><surname>Berk</surname><given-names>L</given-names></name>
<name><surname>Castle</surname><given-names>D</given-names></name>
</person-group> (<year>2004</year>) <article-title>A collaborative approach to the treatment alliance in bipolar disorder</article-title>. <source>Bipolar Disorders</source> <volume>6</volume>: <fpage>504</fpage>–<lpage>518</lpage>.</citation>
</ref>
<ref id="bibr9-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bovbjerg</surname><given-names>DH</given-names></name>
<name><surname>Redd</surname><given-names>WH</given-names></name>
<name><surname>Jacobsen</surname><given-names>PB</given-names></name>
<etal/></person-group>. (<year>1992</year>) <article-title>An experimental analysis of classically conditioned nausea during cancer chemotherapy</article-title>. <source>Psychosomatic Medicine</source> <volume>54</volume>: <fpage>623</fpage>–<lpage>637</lpage>.</citation>
</ref>
<ref id="bibr10-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Casper</surname><given-names>RC</given-names></name>
<name><surname>Tollefson</surname><given-names>GD</given-names></name>
<name><surname>Nilsson</surname><given-names>ME</given-names></name>
</person-group> (<year>2001</year>) <article-title>No gender differences in placebo responses of patients with major depressive disorder</article-title>. <source>Biological Psychiatry</source> <volume>49</volume>: <fpage>158</fpage>–<lpage>160</lpage>.</citation>
</ref>
<ref id="bibr11-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>JA</given-names></name>
<name><surname>Papakostas</surname><given-names>GI</given-names></name>
<name><surname>Youn</surname><given-names>SJ</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group</article-title>. <source>Journal of Clinical Psychiatry</source> <volume>72</volume>: <fpage>1669</fpage>–<lpage>1676</lpage>.</citation>
</ref>
<ref id="bibr12-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Colagiuri</surname><given-names>B</given-names></name>
<name><surname>Zachariae</surname><given-names>R</given-names></name>
</person-group> (<year>2010</year>) <article-title>Patient expectancy and post-chemotherapy nausea: A meta-analysis</article-title>. <source>Annals of Behavioral Medicine</source> <volume>40</volume>: <fpage>3</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr13-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Colloca</surname><given-names>L</given-names></name>
<name><surname>Lopiano</surname><given-names>L</given-names></name>
<name><surname>Lanotte</surname><given-names>M</given-names></name>
<etal/></person-group>. (<year>2004</year>) <article-title>Overt versus covert treatment for pain, anxiety, and Parkinson’s disease</article-title>. <source>Lancet Neurology</source> <volume>3</volume>: <fpage>679</fpage>–<lpage>684</lpage>.</citation>
</ref>
<ref id="bibr14-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Colloca</surname><given-names>L</given-names></name>
<name><surname>Petrovic</surname><given-names>P</given-names></name>
<name><surname>Wager</surname><given-names>TD</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>How the number of learning trials affects placebo and nocebo responses</article-title>. <source>Pain</source> <volume>151</volume>: <fpage>430</fpage>–<lpage>439</lpage>.</citation>
</ref>
<ref id="bibr15-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Colloca</surname><given-names>L</given-names></name>
<name><surname>Sigaudo</surname><given-names>M</given-names></name>
<name><surname>Benedetti</surname><given-names>F</given-names></name>
</person-group> (<year>2008</year>) <article-title>The role of learning in nocebo and placebo effects</article-title>. <source>Pain</source> <volume>136</volume>: <fpage>211</fpage>–<lpage>218</lpage>.</citation>
</ref>
<ref id="bibr16-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>C</given-names></name>
<name><surname>Ralevski</surname><given-names>E</given-names></name>
<name><surname>Kennedy</surname><given-names>SH</given-names></name>
<etal/></person-group>. (<year>1995</year>) <article-title>The role of personality factors in the reporting of side effect complaints to moclobemide and placebo: a study of healthy male and female volunteers</article-title>. <source>Journal of Clinical Psychopharmacology</source> <volume>15</volume>: <fpage>347</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr17-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De la Cruz</surname><given-names>M</given-names></name>
<name><surname>Hui</surname><given-names>D</given-names></name>
<name><surname>Parsons</surname><given-names>HA</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer</article-title>. <source>Cancer</source> <volume>116</volume>: <fpage>766</fpage>–<lpage>774</lpage>.</citation>
</ref>
<ref id="bibr18-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Di Blasi</surname><given-names>Z</given-names></name>
<name><surname>Harkness</surname><given-names>E</given-names></name>
<name><surname>Ernst</surname><given-names>E</given-names></name>
<etal/></person-group>. (<year>2001</year>) <article-title>Influence of context effects on health outcomes: a systematic review</article-title>. <source>Lancet</source> <volume>357</volume>: <fpage>757</fpage>–<lpage>762</lpage>.</citation>
</ref>
<ref id="bibr19-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drici</surname><given-names>MD</given-names></name>
<name><surname>Raybaud</surname><given-names>F</given-names></name>
<name><surname>De Lunardo</surname><given-names>C</given-names></name>
<etal/></person-group>. (<year>1995</year>) <article-title>Influence of the behaviour pattern on the nocebo response of healthy volunteers</article-title>. <source>British Journal of Clinical Pharmacology</source> <volume>39</volume>: <fpage>204</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr20-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Edwards</surname><given-names>A</given-names></name>
<name><surname>Elwyn</surname><given-names>G</given-names></name>
<name><surname>Covey</surname><given-names>J</given-names></name>
<etal/></person-group>. (<year>2001</year>) <article-title>Presenting risk information — a review of the effects of "framing" and other manipulations on patient outcomes</article-title>. <source>Journal of Health Communication</source> <volume>6</volume>: <fpage>61</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr21-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Feldman</surname><given-names>PJ</given-names></name>
<name><surname>Cohen</surname><given-names>S</given-names></name>
<name><surname>Doyle</surname><given-names>WJ</given-names></name>
<etal/></person-group>. (<year>1999</year>) <article-title>The impact of personality on the reporting of unfounded symptoms and illness</article-title>. <source>Journal of Personality and Social Psychology</source> <volume>77</volume>: <fpage>370</fpage>–<lpage>378</lpage>.</citation>
</ref>
<ref id="bibr22-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geers</surname><given-names>AL</given-names></name>
<name><surname>Helfer</surname><given-names>SG</given-names></name>
<name><surname>Kosbab</surname><given-names>K</given-names></name>
<etal/></person-group>. (<year>2005</year>) <article-title>Reconsidering the role of personality in placebo effects: Dispositional optimism, situational expectations, and the placebo response</article-title>. <source>Journal of Psychosomatic Research</source> <volume>58</volume>: <fpage>121</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr23-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Geers</surname><given-names>AL</given-names></name>
<name><surname>Kosbab</surname><given-names>K</given-names></name>
<name><surname>Helfer</surname><given-names>SG</given-names></name>
<etal/></person-group>. (<year>2007</year>) <article-title>Further evidence for individual differences in placebo responding: An interactionist perspective</article-title>. <source>Journal of Psychosomatic Research</source> <volume>62</volume>: <fpage>563</fpage>–<lpage>570</lpage>.</citation>
</ref>
<ref id="bibr24-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grimes</surname><given-names>DA</given-names></name>
<name><surname>Schulz</surname><given-names>KF</given-names></name>
</person-group> (<year>2011</year>) <article-title>Nonspecific side effects of oral contraceptives: Nocebo or noise?</article-title> <source>Contraception</source> <volume>83</volume>: <fpage>5</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr25-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hahn</surname><given-names>RA</given-names></name>
</person-group> (<year>1997</year>) <article-title>The nocebo phenomenon: concept, evidence, and implications for public health</article-title>. <source>Preventive Medicine</source> <volume>26</volume>: <fpage>607</fpage>–<lpage>611</lpage>.</citation>
</ref>
<ref id="bibr26-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hiller</surname><given-names>W</given-names></name>
<name><surname>Rief</surname><given-names>W</given-names></name>
<name><surname>Brahler</surname><given-names>E</given-names></name>
</person-group> (<year>2006</year>) <article-title>Somatization in the population: from mild bodily misperceptions to disabling symptoms</article-title>. <source>Social Psychiatry and Psychiatric Epidemiology</source> <volume>41</volume>: <fpage>704</fpage>–<lpage>712</lpage>.</citation>
</ref>
<ref id="bibr27-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johansen</surname><given-names>O</given-names></name>
<name><surname>Brox</surname><given-names>J</given-names></name>
<name><surname>Flaten</surname><given-names>MA</given-names></name>
</person-group> (<year>2003</year>) <article-title>Placebo and nocebo responses, cortisol, and circulating beta-endorphin</article-title>. <source>Psychosomatic Medicine</source> <volume>65</volume>: <fpage>786</fpage>–<lpage>790</lpage>.</citation>
</ref>
<ref id="bibr28-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kennedy</surname><given-names>WP</given-names></name>
</person-group> (<year>1961</year>) <article-title>The nocebo reaction</article-title>. <source>Medical World</source> <volume>95</volume>: <fpage>203</fpage>–<lpage>205</lpage>.</citation>
</ref>
<ref id="bibr29-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Klosterhalfen</surname><given-names>S</given-names></name>
<name><surname>Kellermann</surname><given-names>S</given-names></name>
<name><surname>Braun</surname><given-names>S</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>Gender and the nocebo response following conditioning and expectancy</article-title>. <source>Journal of Psychosomatic Research</source> <volume>66</volume>: <fpage>323</fpage>–<lpage>328</lpage>.</citation>
</ref>
<ref id="bibr30-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kong</surname><given-names>J</given-names></name>
<name><surname>Gollub</surname><given-names>RL</given-names></name>
<name><surname>Polich</surname><given-names>G</given-names></name>
<etal/></person-group>. (<year>2008</year>) <article-title>A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect</article-title>. <source>Journal of Neuroscience</source> <volume>28</volume>: <fpage>13354</fpage>–<lpage>13362</lpage>.</citation>
</ref>
<ref id="bibr31-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koyama</surname><given-names>T</given-names></name>
<name><surname>McHaffie</surname><given-names>JG</given-names></name>
<name><surname>Laurienti</surname><given-names>PJ</given-names></name>
<etal/></person-group>. (<year>2005</year>) <article-title>The subjective experience of pain: Where expectations become reality</article-title>. <source>Proceedings of the National Academy of Sciences U S A</source> <volume>102</volume>: <fpage>12950</fpage>–<lpage>12955</lpage>.</citation>
</ref>
<ref id="bibr32-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liccardi</surname><given-names>G</given-names></name>
<name><surname>Senna</surname><given-names>G</given-names></name>
<name><surname>Russo</surname><given-names>M</given-names></name>
<etal/></person-group>. (<year>2004</year>) <article-title>Evaluation of the nocebo effect during oral challenge in patients with adverse drug reactions</article-title>. <source>Journal of Investigational Allergology and Clinical Immunology</source> <volume>14</volume>: <fpage>104</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr33-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Link</surname><given-names>J</given-names></name>
<name><surname>Haggard</surname><given-names>R</given-names></name>
<name><surname>Kelly</surname><given-names>K</given-names></name>
<etal/></person-group>. (<year>2006</year>) <article-title>Placebo/nocebo symptom reporting in a sham herbal supplement trial</article-title>. <source>Evaluation &amp; the Health Professions</source> <volume>29</volume>: <fpage>394</fpage>–<lpage>406</lpage>.</citation>
</ref>
<ref id="bibr34-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lombardi</surname><given-names>C</given-names></name>
<name><surname>Gargioni</surname><given-names>S</given-names></name>
<name><surname>Canonica</surname><given-names>GW</given-names></name>
<etal/></person-group>. (<year>2008</year>) <article-title>The nocebo effect during oral challenge in subjects with adverse drug reactions</article-title>. <source>European Annals of Allergy and Clinical Immunology</source> <volume>40</volume>: <fpage>138</fpage>–<lpage>141</lpage>.</citation>
</ref>
<ref id="bibr35-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mechanic</surname><given-names>D</given-names></name>
</person-group> (<year>1972</year>) <article-title>Social psychologic factors affecting the presentation of bodily complaints</article-title>. <source>New England Journal of Medicine</source> <volume>286</volume>: <fpage>1132</fpage>–<lpage>1139</lpage>.</citation>
</ref>
<ref id="bibr36-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meynen</surname><given-names>G</given-names></name>
<name><surname>Swaab</surname><given-names>DF</given-names></name>
</person-group> (<year>2011</year>) <article-title>Why medication in involuntary treatment may be less effective: the placebo/nocebo effect</article-title>. <source>Medical Hypotheses</source> <volume>77</volume>: <fpage>993</fpage>–<lpage>995</lpage>.</citation>
</ref>
<ref id="bibr37-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mitsikostas</surname><given-names>DD</given-names></name>
<name><surname>Chalarakis</surname><given-names>NG</given-names></name>
<name><surname>Mantonakis</surname><given-names>LI</given-names></name>
<etal/></person-group>. (<year>2012</year>) <article-title>Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice</article-title>. <source>European Journal of Neurology</source> <volume>19</volume>: <fpage>672</fpage>–<lpage>680</lpage>.</citation>
</ref>
<ref id="bibr38-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mitsikostas</surname><given-names>DD</given-names></name>
<name><surname>Mantonakis</surname><given-names>LI</given-names></name>
<name><surname>Chalarakis</surname><given-names>NG</given-names></name>
</person-group> (<year>2011</year>) <article-title>Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches</article-title>. <source>Cephalalgia</source> <volume>31</volume>: <fpage>550</fpage>–<lpage>561</lpage>.</citation>
</ref>
<ref id="bibr39-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mondaini</surname><given-names>N</given-names></name>
<name><surname>Gontero</surname><given-names>P</given-names></name>
<name><surname>Giubilei</surname><given-names>G</given-names></name>
<etal/></person-group>. (<year>2007</year>) <article-title>Finasteride 5 mg and sexual side effects: How many of these are related to a nocebo phenomenon?</article-title> <source>Journal of Sexual Medicine</source> <volume>4</volume>: <fpage>1708</fpage>–<lpage>1712</lpage>.</citation>
</ref>
<ref id="bibr40-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Myers</surname><given-names>MG</given-names></name>
<name><surname>Cairns</surname><given-names>JA</given-names></name>
<name><surname>Singer</surname><given-names>J</given-names></name>
</person-group> (<year>1987</year>) <article-title>The consent form as a possible cause of side effects</article-title>. <source>Clinical Pharmacology &amp; Therapeutics</source> <volume>42</volume>: <fpage>250</fpage>–<lpage>253</lpage>.</citation>
</ref>
<ref id="bibr41-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O–Connor</surname><given-names>AM</given-names></name>
<name><surname>Pennie</surname><given-names>RA</given-names></name>
<name><surname>Dales</surname><given-names>RE</given-names></name>
</person-group> (<year>1996</year>) <article-title>Framing effects on expectations, decisions, and side effects experienced: the case of influenza immunization</article-title>. <source>Journal of Clinical Epidemiology</source> <volume>49</volume>: <fpage>1271</fpage>–<lpage>1276</lpage>.</citation>
</ref>
<ref id="bibr42-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Papadopoulos</surname><given-names>D</given-names></name>
<name><surname>Mitsikostas</surname><given-names>DD</given-names></name>
</person-group> (<year>2012</year>) <article-title>A meta-analytic approach to estimating nocebo effects in neuropathic pain trials</article-title>. <source>Journal of Neurology</source> <volume>259</volume>: <fpage>436</fpage>–<lpage>447</lpage>.</citation>
</ref>
<ref id="bibr43-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Papadopoulos</surname><given-names>D</given-names></name>
<name><surname>Mitsikostas</surname><given-names>DD</given-names></name>
</person-group> (<year>2011</year>) <article-title>Nocebo effects in multiple sclerosis trials: a meta-analysis</article-title>. <source>Multiple Sclerosis Journal</source> <volume>16</volume>: <fpage>816</fpage>–<lpage>828</lpage>.</citation>
</ref>
<ref id="bibr44-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Procci</surname><given-names>WR</given-names></name>
</person-group> (<year>1981</year>) <article-title>Psychological factors associated with severe abuse of the hemodialysis diet</article-title>. <source>General Hospital Psychiatry</source> <volume>3</volume>: <fpage>111</fpage>–<lpage>118</lpage>.</citation>
</ref>
<ref id="bibr45-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rief</surname><given-names>W</given-names></name>
<name><surname>Avorn</surname><given-names>J</given-names></name>
<name><surname>Barsky</surname><given-names>AJ</given-names></name>
</person-group> (<year>2006</year>) <article-title>Medication-attributed adverse effects in placebo groups: implications for assessment of adverse effects</article-title>. <source>Archives of Internal Medicine</source> <volume>166</volume>: <fpage>155</fpage>–<lpage>160</lpage>.</citation>
</ref>
<ref id="bibr46-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rief</surname><given-names>W</given-names></name>
<name><surname>Hessel</surname><given-names>A</given-names></name>
<name><surname>Braehler</surname><given-names>E</given-names></name>
</person-group> (<year>2001</year>) <article-title>Somatization symptoms and hypochondriacal features in the general population</article-title>. <source>Psychosomatic Medicine</source> <volume>63</volume>: <fpage>595</fpage>–<lpage>602</lpage>.</citation>
</ref>
<ref id="bibr47-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rief</surname><given-names>W</given-names></name>
<name><surname>Nestoriuc</surname><given-names>Y</given-names></name>
<name><surname>von Lilienfeld-Toal</surname><given-names>A</given-names></name>
<etal/></person-group>. (<year>2009</year>) <article-title>Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: A systematic review and meta-analysis</article-title>. <source>Drug Safety</source> <volume>32</volume>: <fpage>1041</fpage>–<lpage>1056</lpage>.</citation>
</ref>
<ref id="bibr48-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rogers</surname><given-names>MP</given-names></name>
</person-group> (<year>2003</year>) <article-title>Headaches and the nocebo effect</article-title>. <source>Headache</source> <volume>43</volume>: <fpage>1113</fpage>–<lpage>1115</lpage>.</citation>
</ref>
<ref id="bibr49-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenzweig</surname><given-names>P</given-names></name>
<name><surname>Brohier</surname><given-names>S</given-names></name>
<name><surname>Zipfel</surname><given-names>A</given-names></name>
</person-group> (<year>1993</year>) <article-title>The placebo effect in healthy volunteers: influence of experimental conditions on the adverse events profile during phase I studies</article-title>. <source>Clinical Pharmacology &amp; Therapeutics</source> <volume>54</volume>: <fpage>578</fpage>–<lpage>583</lpage>.</citation>
</ref>
<ref id="bibr50-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schweiger</surname><given-names>A</given-names></name>
<name><surname>Parducci</surname><given-names>A</given-names></name>
</person-group> (<year>1981</year>) <article-title>Nocebo: The psychologic induction of pain</article-title>. <source>The Pavlovian Journal of Biological Sciences</source> <volume>16</volume>: <fpage>140</fpage>–<lpage>143</lpage>.</citation>
</ref>
<ref id="bibr51-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scott</surname><given-names>DJ</given-names></name>
<name><surname>Stohler</surname><given-names>CS</given-names></name>
<name><surname>Egnatuk</surname><given-names>CM</given-names></name>
<etal/></person-group>. (<year>2008</year>) <article-title>Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses</article-title>. <source>Archives of General Psychiatry</source> <volume>65</volume>: <fpage>220</fpage>–<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr52-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sibille</surname><given-names>M</given-names></name>
<name><surname>Deigat</surname><given-names>N</given-names></name>
<name><surname>Janin</surname><given-names>A</given-names></name>
<etal/></person-group>. (<year>1998</year>) <article-title>Adverse events in phase-I studies: a report in 1015 healthy volunteers</article-title>. <source>European Journal of Clinical Pharmacology</source> <volume>54</volume>: <fpage>13</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr53-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Silvestri</surname><given-names>A</given-names></name>
<name><surname>Galetta</surname><given-names>P</given-names></name>
<name><surname>Cerquetani</surname><given-names>E</given-names></name>
<etal/></person-group>. (<year>2003</year>) <article-title>Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo</article-title>. <source>European Heart Journal</source> <volume>24</volume>: <fpage>1928</fpage>–<lpage>1932</lpage>.</citation>
</ref>
<ref id="bibr54-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Strohle</surname><given-names>A</given-names></name>
</person-group> (<year>2000</year>) <article-title>Increased response to a putative panicogenic nocebo administration in female patients with panic disorder</article-title>. <source>Journal of Psychiatric Research</source> <volume>34</volume>: <fpage>439</fpage>–<lpage>442</lpage>.</citation>
</ref>
<ref id="bibr55-0004867412464717">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Thaler</surname><given-names>RH</given-names></name>
<name><surname>Sunstein</surname><given-names>CR</given-names></name>
</person-group> (<year>2008</year>) <source>Nudge: Improving Decisions about Health, Wealth, and Happiness</source>. <publisher-loc>New Haven</publisher-loc>: <publisher-name>Yale University Press</publisher-name>.</citation>
</ref>
<ref id="bibr56-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Uhlenhuth</surname><given-names>EH</given-names></name>
<name><surname>Alexander</surname><given-names>PE</given-names></name>
<name><surname>Dempsey</surname><given-names>GM</given-names></name>
<etal/></person-group>. (<year>1998</year>) <article-title>Medication side effects in anxious patients: Negative placebo responses?</article-title> <source>Journal of Affective Disorders</source> <volume>47</volume>: <fpage>183</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr57-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Laarhoven</surname><given-names>AI</given-names></name>
<name><surname>Vogelaar</surname><given-names>ML</given-names></name>
<name><surname>Wilder-Smith</surname><given-names>OH</given-names></name>
<etal/></person-group>. (<year>2011</year>) <article-title>Induction of nocebo and placebo effects on itch and pain by verbal suggestions</article-title>. <source>Pain</source> <volume>152</volume>: <fpage>1486</fpage>–<lpage>1494</lpage>.</citation>
</ref>
<ref id="bibr58-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Varelmann</surname><given-names>D</given-names></name>
<name><surname>Pancaro</surname><given-names>C</given-names></name>
<name><surname>Cappiello</surname><given-names>EC</given-names></name>
<etal/></person-group>. (<year>2010</year>) <article-title>Nocebo-induced hyperalgesia during local anesthetic injection</article-title>. <source>Anesthesia &amp; Analgesia</source> <volume>110</volume>: <fpage>868</fpage>–<lpage>870</lpage>.</citation>
</ref>
<ref id="bibr59-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zikmund-Fisher</surname><given-names>BJ</given-names></name>
<name><surname>Fagerlin</surname><given-names>A</given-names></name>
<name><surname>Roberts</surname><given-names>TR</given-names></name>
<etal/></person-group>. (<year>2008</year>) <article-title>Alternate methods of framing information about medication side effects: incremental risk versus total risk of occurrence</article-title>. <source>Journal of Health Communication</source> <volume>13</volume>: <fpage>107</fpage>–<lpage>124</lpage>.</citation>
</ref>
<ref id="bibr60-0004867412464717">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zopf</surname><given-names>Y</given-names></name>
<name><surname>Rabe</surname><given-names>C</given-names></name>
<name><surname>Neubert</surname><given-names>A</given-names></name>
<etal/></person-group>. (<year>2008</year>) <article-title>Women encounter ADRs more often than do men</article-title>. <source>European Journal of Clinical Pharmacology</source> <volume>64</volume>: <fpage>999</fpage>–<lpage>1004</lpage>.</citation>
</ref></ref-list>
</back>
</article>